A method for producing a cell population containing cardiomyocytes, including (1) a step of bringing a histone deacetylase inhibitor into contact with a cell population containing cardiomyocytes and cells other than cardiomyocytes, the cell population being obtained by culturing pluripotent stem cells in a medium for cardiomyocyte differentiation, and (2) a step of culturing the cell population is provided by the present invention.

Methods and compositions are described herein that involve expansion of hematopoietic stem cells and/or hematopoietic progenitor cells.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

Disclosed are compositions, in particular, organoid compositions, derived from more than one donor cell. Further disclosed are methods of making compositions, for example, organoid compositions, that comprise a differentiated cell population derived from more than one donor cell. Donor cells may include, for example, a precursor cell such as an embryonic stem cell or other precursor cell. The disclosed methods use synchronization conditions to produce a synchronized pooled-precursor cell population, which may then be differentiated into an organoid composition. Methods of using the compositions are also disclosed.

This invention provides improved methods for generation of hematopoietic precursor cells from a pluripotent stem cell and hematopoietic precursor cells generated thereof. The hematopoietic precursor cells express CXCR4 or runx1c and are capable of homing and/or engraftment in bone marrow.

The present disclosure relates to recombinant microorganisms having an improved ethylene producing ability, methods of producing the same, and methods of producing ethylene. A benefit of the recombinant microorganisms and the methods disclosed herein can include increased production of ethylene from microbial cultures. An additional benefit can be the use of carbon dioxide to produce bio-ethylene useful as a feedstock for the production of plastics, textiles, and chemical materials, and for use in other applications. Another benefit of the methods and systems disclosed herein can include reduction of excess carbon dioxide from the environment.

Processes, systems and microorganisms are described herein for producing glycolate from ethylene glycol. The processes generally comprise supplying a fermentation broth into a fermentation vessel, wherein the fermentation broth comprises ethylene glycol and a microorganism having a functional metabolic pathway for utilizing ethylene glycol as a carbon source. In a growth phase, an oxygen-containing gas is injected into the fermentation broth to provide oxygen bio-availability conditions to promote cell growth of the microorganism and limit accumulation of glycolate in the fermentation broth. In a production phase, an oxygen-containing gas is injected into the fermentation broth to provide oxygen bio-availability conditions to promote production of glycolate from ethylene glycol by the microorganism and accumulation of the glycolate in the fermentation broth, to produce a glycolate enriched broth.

Disclosed are methods related to culturing anaerobic bacteria in a microaerobic environment. The method comprises culturing in a microaerobic environment an anaerobic bacteria with an aerobic microorganism. The microaerobic environment may not require gas pre-treatment to remove trace O.sub.2. Also disclosed are methods related to producing a product, syngas fermentation, and gas valorization. The method comprises culturing in a microaerobic environment an anaerobic bacteria with an aerobic microorganism.

A method for arterial endothelial-enhanced functional T cell generation is provided. In the method, arterial endothelial cells enhance functional T cell generation by promoting the generation of hematopoietic progenitor cells with T-lineage bias. The first stage of T cell differentiation from human pluripotent stem cells (hPSCs) is optimized, and it is found that hPSC-derived autologous arterial endothelial cells increase the T cell potential of hematopoietic progenitor cells. Moreover, the T cells generated by arterial endothelial cell priming share similar function to that of human peripheral blood T cells. hPSC-derived CD19-CAR-T cells have been verified to have tumor-killing effects both in vivo and in vitro. The established hPSC-T differentiation system would provide a valuable resource for chimeric antigen receptor T cell (CAR-T) therapy.

The present invention relates to a protein variant, a microorganism with enhanced carbon monoxide (CO) availability comprising the variant, and a use thereof.